alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>

                                  EXHIBIT 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the Quarterly Report of Central Wireless,  Inc. (the
"Company")  on Form 10-QSB for the period  ended June 30, 2003 as filed with the
Securities and Exchange  Commission on the date hereof (the  "Report"),  each of
the  undersigned,  in the capacities and on the dates  indicated  below,  hereby
certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that to his knowledge:

         1. The Report fully complies with the  requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

         2. The  information  contained in the Report  fairly  presents,  in all
material  respects,  the  financial  condition  and results of  operation of the
Company.

Date: August 14, 2003           By: /s/ Kenneth W. Brand
                                    -------------------------------------------
                                Name: Kenneth W. Brand
                                Title: Chief Executive Officer and Acting Chief
                                       Executive Officer


         A signed original of this written statement required by Section 906, or
other  document  authentications,   acknowledging,  or  otherwise  adopting  the
signature  that  appears in typed form  within  the  electronic  version of this
written  statement  required  by  Section  906,  has been  provided  to  Central
Wireless,  Inc. and will be retained by Central Wireless,  Inc. and furnished to
the Securities and Exchange Commission or its staff upon request.
<PAGE>   1
                                                                    Exhibit 99.3
                                    FORM OF
                          FINE.COM INTERNATIONAL CORP.

                  PROXY FOR SPECIAL MEETING OF SHAREHOLDERS

                                 AUGUST 31, 1999

                SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

      The undersigned hereby appoints Daniel M. Fine and Timothy J. Carroll, and
each or both of them, proxies, with full power of substitution to vote all
shares of stock of fine.com International Corp. which the undersigned is
entitled to vote at the Special Meeting of Shareholders of fine.com
International Corp., to be held on Tuesday, August 31, 1999, at 8:00 a.m., at
the Century Square Plaza Building, 16th Floor, Room 1625, located at 1501 Fourth
Avenue, Seattle, Washington and at any adjournment or postponement thereof, upon
matters set forth in the Notice of Special Meeting of Shareholders and Proxy
Statement/Prospectus dated August 10, 1999, a copy of which has been received by
the undersigned. The proxies are further authorized to vote, in their
discretion, upon such other business as may properly come before the meeting or
any adjournment or postponement thereof.

      THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS DIRECTED, OR, IF NO
DIRECTION IS GIVEN, WILL BE VOTED FOR THE MERGER AGREEMENT AND THE MERGER AS
DESCRIBED IN THE PROPOSAL.

      Please mark your votes as indicated in this example.   [X]


      1.    To consider and vote upon approval of the Agreement and Plan of
            Merger dated as of May 17, 1999 and amended and restated as of
            August 5, 1999, among fine.com, ARIS Corporation, ARIS Interactive,
            Inc., a wholly owned subsidiary of ARIS, Daniel M. Fine, Frank Hadam
            and Herbert L. Fine, pursuant to which fine.com will be merged with
            and into ARIS Interactive.

            FOR  [ ]         AGAINST  [ ]         ABSTAIN  [ ]

      2.    To transact such other business as may properly come before the
            meeting and any adjournment or postponement thereof.

                            Date:             , 1999
                                  ------------

                            Signature(s) of Shareholder(s)

                            ----------------------------------------------
                            Print Name(s)

                            (If signing as attorney, executor, trustee or
                            guardian, please give your full title as such. If
                            shares are held jointly, each holder should sign.)

                            [ ] Check this box if you plan on attending the
                            Special Meeting of Shareholders in person.
§ 573.230 Calcium formate. The food additive calcium formate may be safely used in the manufacture of complete swine and poultry feeds in accordance with the following prescribed conditions: ( a ) The additive is manufactured by the reaction of butyraldehyde, formaldehyde, calcium hydroxide, and formic acid in water followed by purification and dried to produce a powder consisting of not less than 99.0 percent calcium formate (CAS 544-17-2). The additive meets the following specifications: ( 1 ) The additive consists of minimum 30.5 percent calcium and minimum 68.5 percent formate.
( 2 ) Trimethylolpropane (TMP) not to exceed 125 parts per million.
( b ) The additive is used or intended for use as a feed acidifying agent, to lower the pH, in complete swine or poultry feeds at levels not to exceed 1.2 percent of the complete feed.
( c ) To ensure safe use of the additive, formic acid and formate salts from all added sources cannot exceed 1.2 percent of complete feed when multiple sources of formic acid and its salts are used in combination.
( d ) To ensure safe use of the additive, in addition to the other information required by the Federal Food, Drug, and Cosmetic Act, the label and labeling shall contain: ( 1 ) The name of the additive.
( 2 ) Adequate directions for use including a statement that calcium formate must be uniformly applied and thoroughly mixed into complete feeds and that the complete feeds so treated shall be labeled as containing calcium formate.
( 3 ) Cautions for use including this statement: Caution: Follow label directions. Formic acid and formate salts from all added sources cannot exceed 1.2 percent of complete feed when multiple sources of formic acid and its salts are used in combination.
( e ) To ensure safe use of the additive, in addition to the other information required by the act and paragraph (d) of this section, the label and labeling shall contain: ( 1 ) Appropriate warnings and safety precautions concerning calcium formate.
( 2 ) Statements identifying calcium formate as a possible severe irritant.
( 3 ) Information about emergency aid in case of accidental exposure as follows. ( i ) Statements reflecting requirements of applicable sections of the Superfund Amendments and Reauthorization Act, and the Occupational Safety and Health Administration's (OSHA) human safety guidance regulations.
( ii ) Contact address and telephone number for reporting adverse reactions or to request a copy of the Safety Data Sheet (SDS).
[88 FR 87671, Dec. 19, 2023]
December 16, 2014

JUDGMENT

The Fourteenth Court of Appeals

JASON RAY BOUCHARD, Appellant

NO. 14-13-00350-CR V.

THE STATE OF TEXAS, Appellee

________________________________

This cause was heard on the transcript of the record of the court below. 

Having considered the record, this Court holds that there was no error in the 

judgment. The Court orders the judgment AFFIRMED.

We further order this decision certified below for observance.
Summary of Agreement to Pay Expenses of Certain Shareholders



 Exhibit 10(m) 
 Alberto-Culver Company 
 Summary of Agreement to Pay Expenses of 
 Certain Shareholders 
 On June 19, 2006,
Alberto-Culver Company entered into an Investment Agreement (the “Investment Agreement”) with Sally Holdings, Inc., New Sally Holdings, Inc., a subsidiary of Alberto-Culver Company, New Aristotle Company, a subsidiary of New Sally
Holdings, Inc. and CDRS Acquisition LLC. In connection with the signing of the Investment Agreement, certain shareholders of Alberto-Culver Company, consisting of trusts for the benefit of Leonard H. Lavin, a director of Alberto-Culver Company, and
Bernice E. Lavin and their descendants, including Carol L. Bernick, the Chairman of the Board of Directors of Alberto-Culver Company (collectively, the “Lavin Family”), and a partnership whose partners are trusts for the benefit of members
of the Lavin Family and Leonard H. Lavin, Bernice E. Lavin and Carol L. Bernick (collectively, the “Shareholders”), entered into a Support Agreement with Alberto-Culver Company, New Sally Holdings, Inc. and CDRS Acquisition LLC. The
Shareholders will also enter into a Stockholders Agreement with New Sally Holdings, Inc. and CDRS Acquisition LLC, which will provide for, among other things, specified governance matters related to New Sally Holdings, Inc. 
 On June 18, 2006, Alberto-Culver agreed to pay up to $100,000 of the fees and expenses of the Shareholders relating to the negotiation of the Support Agreement and
the Stockholders Agreement and matters incident to the transactions contemplated by the Investment Agreement.
In The Matter Of 

### SERVED: July 1, 2015 

### U.S. DEPARTMENT OF TRANSPORTATION OFFICE OF HEARINGS WASHINGTON, DC

DocketNo. FAA-2014-0324 GLOBALAIRCRAFT INTERIORS, INC. ) ) ) ) ) ) Case No. 2011EA110043 Respondent
ORDER SETTING LITIGATION SCHEDULING CONFERENCE .··',_

On May 20, 2015 an Order Setting Deadlines and New Status Conference was filed. Pursuantto this May 20, 2015 Order, theparties appearedby telephone for a Status Conference on Tuesday, June 30, 2015 at 1:30pm Eastern time, and reported on the status ofthe proceedings. During this Status Conference, both parties agreed that they needed additional time to discuss settlement options and the status ofthe case.

· Having reviewed and consideredthe case file, all pleadings and motions, all relevant caselaw, statutes, regulations, rules, and authority, and being fully advised; IT IS HEREBY ORDERED: 1. On Tuesday, August 11,2015 at 1:30pm Eastern time, theparties shall re-convene for a Litigation Scheduling Conference. Atthat time, the parties will discuss discovery deadlines and other litigation matters, and schedule a new Hearing date. To access the Court's conference line, the parties shall call 202-493-2343. 2. For clarifications ofthis order or questions withregard to the proceduresto be followed in this case, please contact Mr. Cody L. Smith, Attorney-Advisor, at the Office of Hearings (202-366-6941).

Attachment: Service ListSERVICE LIST- BY U.S. MAIL

Federal Aviation Administration 800 Independence Avenue, S.W. Washington, DC 20591 ORIGINAL & ONE COPY

Attention: Hearing Docket Clerk, AGC-430 Wilbur Wright Building-Suite2W1000 1
Mr. Zachary M. Berman Complainant's Counsel Federal Aviation Administration Office ofthe Regional Counsel 1Aviation Plaza Jamaica, NY 11434 TEL: 718-553-3258 FAX:**718~995-5699** Mr. Robert Roth Respondent's LayRepresentative 2075 SmithtownAvenue Ronkonkoma, NY 11779 TEL: 631-981-8470 Judge J.E. Sullivan· US. Administrative LawJudge Office ofHearings, M-20 U.S. Department ofTransportation ONE COPY

1200 NewJersey Avenue, S.E. (E11-310) Washington, DC 20590 TEL: 202-366-6941 FAX: 202-366-7536 DocketNo. FAA-2014-0324 (Civil Penalty Action)

1 Service was by U.S. Mail. For service in person orby expedited courier, use the following address: Federal Aviation Administration, 600 Independence Avenue, S.W., Wilbur Wright Building-Suite 2W 1000, Washington, DC 20591; Attention: Hearing Docket Clerk, AGC-430.
EXHIBIT 32  SECTION 906 CERTIFICATIONS



Each of the undersigned hereby certifies, in accordance with 18 U.S.C. 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Provena Foods Inc. (the Company), that, to his knowledge, the Quarterly Report of the Company on Form 10-Q for the period ended
September 30, 2005, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in such report fairly presents, in all material respects, the
financial condition and results of operation of the Company.



Date:
November 3, 2005



/s/ Theodore L. ArenaTheodore L. Arena, Chief Executive Officer/s/ Thomas J. MulroneyThomas J. Mulroney, Chief Financial Officer
# C_2015311EN.01001302.xml

| 21.9.2015 | EN | Official Journal of the European Union | C 311/13 |
| --- | --- | --- | --- |

21.9.2015

EN

Official Journal of the European Union

C 311/13

---

Appeal brought on 12 December 2014 by Junited Autoglas Deutschland GmbH & Co. KG against the judgment of the General Court (Fifth Chamber) delivered on 16 October 2014 in Case T-297/13: Junited Autoglas Deutschland GmbH & Co. KG v Office for Harmonisation in the Internal Market (Trade Marks and Designs)

(Case C-579/14 P)

(2015/C 311/16)

Language of the case: English

Parties

Parties

Appellant: Junited Autoglas Deutschland GmbH & Co. KG (represented by: C. Weil, Rechtsanwalt)

Appellant:

Other party to the proceedings: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Other party to the proceedings:

By order of 4 June 2015 the Court of Justice (Sixth Chamber) has dismissed the appeal and ordered Junited Autoglas Deutschland GmbH & Co. KG to pay the costs.

---
§ 522.1698 Pentazocine. ( a ) *Specifications.* Each milliliter of solution contains pentazocine lactate equivalent to 30 milligrams (mg) of pentazocine base.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Horses* — ( i ) *Amount.* Administer 0.15 mg pentazocine base per pound of body weight daily by intravenous or intramuscular injection. In cases of severe pain, a second dose is recommended by intramuscular injection 10 to 15 minutes after the initial dose at the same level.
( ii ) *Indications for use.* For symptomatic relief of pain due to colic.
( iii ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Dogs* — ( i ) *Amount.* Administer 0.75 to 1.50 mg of pentazocine base per pound of body weight by intramuscular injection.
( ii ) *Indications for use.* For amelioration of pain accompanying postoperative recovery, fracture, trauma, and spinal disorders.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[42 FR 31450, June 21, 1977, as amended at 42 FR 36995, July 19, 1977; 47 FR 5409, Feb. 5, 1982; 55 FR 23076, June 6, 1990; 79 FR 16193, Mar. 25, 2014. Redesignated at 86 FR 61685, Nov. 8, 2021, and further redesignated at 88 FR 14899, Mar. 10, 2023]
<TABLE> <S> <C>

<ARTICLE>                                            9
<MULTIPLIER>                                   1,000
       
<S>                                            <C>
<PERIOD-TYPE>                                  YEAR
<FISCAL-YEAR-END>                              SEP-30-1996
<PERIOD-END>                                   SEP-30-1996
<CASH>                                             834
<INT-BEARING-DEPOSITS>                          16,730
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                      1,881
<INVESTMENTS-CARRYING>                          10,503
<INVESTMENTS-MARKET>                            10,399
<LOANS>                                         77,799
<ALLOWANCE>                                        297
<TOTAL-ASSETS>                                 108,953
<DEPOSITS>                                      76,946
<SHORT-TERM>                                         0
<LIABILITIES-OTHER>                              1,785
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           218
<OTHER-SE>                                      30,004
<TOTAL-LIABILITIES-AND-EQUITY>                 108,953
<INTEREST-LOAN>                                  5,970
<INTEREST-INVEST>                                  433
<INTEREST-OTHER>                                 1,309
<INTEREST-TOTAL>                                 7,712
<INTEREST-DEPOSIT>                               3,901
<INTEREST-EXPENSE>                                   0
<INTEREST-INCOME-NET>                            3,811
<LOAN-LOSSES>                                        8
<SECURITIES-GAINS>                                   0
<EXPENSE-OTHER>                                  2,225
<INCOME-PRETAX>                                  1,679
<INCOME-PRE-EXTRAORDINARY>                       1,679
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     1,090
<EPS-PRIMARY>                                     0.55
<EPS-DILUTED>                                        0
<YIELD-ACTUAL>                                    3.57
<LOANS-NON>                                          0
<LOANS-PAST>                                       866
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                                   297
<CHARGE-OFFS>                                        7
<RECOVERIES>                                         0
<ALLOWANCE-CLOSE>                                  297
<ALLOWANCE-DOMESTIC>                               297
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0
        


</TABLE>
§ 556.304 Gonadotropin. ( a ) *Acceptable daily intake (ADI).* The ADI for residues of total gonadotropins (human chorionic gonadotropin and pregnant mare serum gonadotropin) is 42.25 International Units per kilogram of body weight per day.
( b ) *Tolerances.* The tolerances for gonadotropin are: ( 1 ) *Cattle.* Edible tissues (excluding milk): Not required.
( 2 ) *Fish.* Edible tissues: Not required.
( 3 ) *Swine.* Edible tissues: Not required.
( c ) *Related conditions of use.* See §§ 522.1079 and 522.1081 of this chapter.
[84 FR 32993, July 11, 2019, as amended at 85 FR 18121, Apr. 1, 2020]
IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 12-40368

GENE’S MACHINE, INCORPORATED; MARK WOOD; TRACY WOOD;

CRAIG WOOD; J.W.,

Plaintiffs-Appellants

v.

UNITED STATES DEPARTMENT OF HOMELAND SECURITY;

ALEJANDRO MAYORKAS; HILDA L. SOLIS; DAVID L. ROARK,

Defendants-Appellees

Appeal from the United States District Court

for the Southern District of Texas

USDC No. 6:11-CV-4

Before BARKSDALE, DENNIS, and GRAVES, Circuit Judges.

PER CURIAM:*

The district court dismissed the complaint of Gene’sMachine, Inc. (“Gene’s

Machine”) and Mark Wood and the Wood family asserting that the defendant

government agencies and officials violated the Administrative Procedure Act

(“APA”), 5 U.S.C. § 706, in denying an I-140 visa petition filed by Gene’s

Machine on behalf of Mark Wood, an alien Gene’s Machine seeks to employ. 

United States Court of Appeals

Fifth Circuit

F I L E D

December 17, 2012

Lyle W. Cayce

Clerk

 Pursuant to 5TH CIR. R. 47.5, the court has determined that this opinion should not *

be published and is not precedent except under the limited circumstances set forth in 5TH CIR.

R. 47.5.4.

 Case: 12-40368 Document: 00512085340 Page: 1 Date Filed: 12/17/2012
No. 12-40368

Gene’s Machine appeals the district court’s dismissal of its claims challenging

a Department of Labor regulation, 20 C.F.R. § 656.30, which was amended in

2007 to provide that a labor certification granted after the effective date of July

16, 2007 expires if not filed with the Department of Homeland Security in

support of an I-140 visa petition within 180 days of the grant of certification, id.

§ 656.30(b)(1), or, as in the case of Gene’s Machine, that a labor certification

granted before the effective date expires if not filed in support of an I-140

petition within 180 days of the effective date, id. § 656.30(b)(2). Gene’s Machine

claims that the amended regulation does not comport with the text of the labor

certification statute, 8 U.S.C. § 1182(a)(5)(A), and is arbitrary and capricious. 

The district court also held that Mark Wood and the Wood family, the intended

beneficiaries of the visa petition who asserted claims identical to those of Gene’s

Machine, lacked Article III standing. 

As to the claims of Gene’s Machine, we affirm the judgment of dismissal

for failure to state a claim essentially for the reasons given by the district court

in its well-reasoned opinion. Gene’s Mach., Inc. v. Dep’t of Homeland Sec., No.

6:11-CV-4, 2012 WL 1067557 (S.D. Tex. Mar. 28, 2012). Given the dismissal of 1

those claims, and because the claims of Mark Wood and the Wood family are the

same as those of Gene’s Machine, the question of the standing of Mark Wood and

the Wood family is moot.

AFFIRMED.

Gene’s Machine asserted additional claims that were dismissed by the district court

1

but were not raised on appeal, including claims asserting violation of due process and

equitable tolling due to ineffective assistance of counsel. We express no opinion on those

claims.

2

 Case: 12-40368 Document: 00512085340 Page: 2 Date Filed: 12/17/2012
Editorial Note on Part 314
Editorial Note: Nomenclature changes to part 314 appear at 69 FR 13717, Mar. 24, 2004; 81 FR 69639, Oct. 6, 2016.

§ 314.106 Foreign data. ( a ) *General.* The acceptance of foreign data in an application generally is governed by § 312.120 of this chapter.
( b ) *As sole basis for marketing approval.* An application based solely on foreign clinical data meeting U.S. criteria for marketing approval may be approved if: ( 1 ) The foreign data are applicable to the U.S. population and U.S. medical practice;
( 2 ) the studies have been performed by clinical investigators of recognized competence; and
( 3 ) the data may be considered valid without the need for an on-site inspection by FDA or, if FDA considers such an inspection to be necessary, FDA is able to validate the data through an on-site inspection or other appropriate means. Failure of an application to meet any of these criteria will result in the application not being approvable based on the foreign data alone. FDA will apply this policy in a flexible manner according to the nature of the drug and the data being considered.
( c ) *Consultation between FDA and applicants.* Applicants are encouraged to meet with agency officials in a “presubmission” meeting when approval based solely on foreign data will be sought.
[50 FR 7493, Feb. 22, 1985, as amended at 55 FR 11580, Mar. 29, 1990]